Careers  |  Sign In  |  Register

Findings Establish PT2385 as a Highly Specific HIF-2 Inhibitor for Patients with Clear Cell RCC


A study published in Clinical Cancer Research, authored by James Brugarolas, MD, PhD, professor of internal medicine (hematology/oncology) and director of the Kidney Cancer Program at UT Southwestern, demonstrated effectiveness of PT2835 in inhibiting HIF-2 (hypoxia-inducible factor 2). The findings of the study showed a core dependency on HIF-2 in metastatic clear cell renal cell carcinoma (ccRCC). The researchers suggested their findings offer a novel approach for fighting ccRCC while maintaining a better quality of life for patients.

Learn more by clicking here.